Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 19 | 2018 | 55 | 3.140 |
Why?
|
| Adenocarcinoma | 10 | 2010 | 321 | 1.100 |
Why?
|
| Pancreatic Neoplasms | 7 | 2006 | 135 | 0.950 |
Why?
|
| Biliary Tract | 2 | 2012 | 7 | 0.680 |
Why?
|
| Biliary Tract Diseases | 2 | 2012 | 12 | 0.680 |
Why?
|
| Cholestasis | 2 | 2012 | 18 | 0.660 |
Why?
|
| Pancreatic Cyst | 3 | 2018 | 4 | 0.610 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2009 | 65 | 0.570 |
Why?
|
| Incidental Findings | 1 | 2017 | 26 | 0.520 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 6 | 0.500 |
Why?
|
| Lymphatic Diseases | 2 | 2012 | 11 | 0.440 |
Why?
|
| Lymph Nodes | 2 | 2012 | 120 | 0.410 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 515 | 0.380 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2018 | 24 | 0.380 |
Why?
|
| Pancreatitis, Acute Necrotizing | 2 | 2018 | 6 | 0.360 |
Why?
|
| Humans | 39 | 2018 | 34562 | 0.340 |
Why?
|
| Colonoscopy | 2 | 2018 | 46 | 0.320 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2010 | 4 | 0.320 |
Why?
|
| Gastrostomy | 1 | 2010 | 17 | 0.310 |
Why?
|
| Retrospective Studies | 11 | 2018 | 3825 | 0.310 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 614 | 0.300 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2008 | 13 | 0.290 |
Why?
|
| Liver Diseases | 1 | 2009 | 76 | 0.290 |
Why?
|
| Pancreatitis, Chronic | 3 | 2016 | 8 | 0.260 |
Why?
|
| Appendiceal Neoplasms | 1 | 2008 | 99 | 0.260 |
Why?
|
| Female | 25 | 2018 | 21532 | 0.260 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2016 | 30 | 0.260 |
Why?
|
| Male | 23 | 2018 | 20740 | 0.260 |
Why?
|
| Esophageal Neoplasms | 4 | 2010 | 44 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 491 | 0.250 |
Why?
|
| Liver | 2 | 2009 | 513 | 0.250 |
Why?
|
| Middle Aged | 20 | 2018 | 12726 | 0.250 |
Why?
|
| Adult | 16 | 2018 | 10030 | 0.250 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 2367 | 0.240 |
Why?
|
| Telomerase | 1 | 2006 | 22 | 0.240 |
Why?
|
| Aged | 16 | 2018 | 11022 | 0.240 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 55 | 0.240 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 265 | 0.230 |
Why?
|
| DNA | 1 | 2006 | 235 | 0.230 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2016 | 22 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2010 | 58 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 124 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 542 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2003 | 45 | 0.190 |
Why?
|
| Veterans | 1 | 2003 | 73 | 0.190 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 4157 | 0.180 |
Why?
|
| Necrosis | 1 | 2018 | 55 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2018 | 25 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2003 | 628 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2018 | 11 | 0.140 |
Why?
|
| Pancreatitis | 3 | 2011 | 20 | 0.140 |
Why?
|
| Deoxycytidine | 3 | 2010 | 66 | 0.140 |
Why?
|
| Curriculum | 2 | 2012 | 217 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 939 | 0.130 |
Why?
|
| Pancreas | 4 | 2010 | 108 | 0.130 |
Why?
|
| Radiopharmaceuticals | 3 | 2010 | 103 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 168 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 91 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2017 | 129 | 0.120 |
Why?
|
| Choledocholithiasis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2016 | 55 | 0.120 |
Why?
|
| Self Concept | 1 | 2016 | 47 | 0.120 |
Why?
|
| Needles | 1 | 2016 | 33 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 267 | 0.110 |
Why?
|
| Colonic Polyps | 2 | 2018 | 17 | 0.110 |
Why?
|
| Esophagectomy | 2 | 2010 | 18 | 0.100 |
Why?
|
| Prognosis | 1 | 2017 | 1606 | 0.100 |
Why?
|
| Abdomen | 1 | 2012 | 52 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2016 | 1355 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 57 | 0.090 |
Why?
|
| Child | 2 | 2016 | 2614 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 89 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 177 | 0.090 |
Why?
|
| Cholelithiasis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Combined Modality Therapy | 6 | 2011 | 590 | 0.080 |
Why?
|
| Comorbidity | 2 | 2011 | 596 | 0.080 |
Why?
|
| Adolescent | 2 | 2016 | 3805 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2016 | 2463 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1032 | 0.080 |
Why?
|
| Young Adult | 1 | 2017 | 2831 | 0.080 |
Why?
|
| Catheterization | 1 | 2010 | 62 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 600 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 703 | 0.070 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 33 | 0.070 |
Why?
|
| Survival Rate | 3 | 2006 | 928 | 0.070 |
Why?
|
| Gallbladder Neoplasms | 1 | 2009 | 35 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 306 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 397 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 230 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 153 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 170 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2007 | 349 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 205 | 0.060 |
Why?
|
| Genes, ras | 1 | 2006 | 27 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2006 | 30 | 0.060 |
Why?
|
| Celiac Plexus | 1 | 2006 | 3 | 0.060 |
Why?
|
| Disease Progression | 2 | 2006 | 634 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 49 | 0.060 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 10 | 0.060 |
Why?
|
| Nerve Block | 1 | 2006 | 63 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2009 | 1508 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 71 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 204 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1607 | 0.060 |
Why?
|
| Vomiting | 1 | 2005 | 23 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 33 | 0.060 |
Why?
|
| Camptothecin | 1 | 2005 | 52 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 73 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2005 | 2 | 0.060 |
Why?
|
| Nausea | 1 | 2005 | 55 | 0.060 |
Why?
|
| Colchicine | 1 | 2005 | 8 | 0.060 |
Why?
|
| Diarrhea | 1 | 2005 | 59 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2005 | 44 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 54 | 0.060 |
Why?
|
| Fatigue | 1 | 2005 | 90 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 21 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 922 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 354 | 0.050 |
Why?
|
| Mutation | 1 | 2006 | 532 | 0.050 |
Why?
|
| Pain | 1 | 2006 | 330 | 0.050 |
Why?
|
| Cholangiography | 2 | 2016 | 12 | 0.050 |
Why?
|
| Genes, erbB-1 | 1 | 2003 | 15 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2003 | 28 | 0.050 |
Why?
|
| Radiotherapy Dosage | 3 | 2010 | 110 | 0.050 |
Why?
|
| Injections | 1 | 2003 | 76 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2007 | 330 | 0.050 |
Why?
|
| Georgia | 1 | 2003 | 14 | 0.050 |
Why?
|
| Angioedema | 1 | 2003 | 3 | 0.050 |
Why?
|
| Viscera | 1 | 2003 | 18 | 0.050 |
Why?
|
| Enalapril | 1 | 2003 | 8 | 0.050 |
Why?
|
| Florida | 1 | 2003 | 41 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3623 | 0.050 |
Why?
|
| Prisoners | 1 | 2003 | 12 | 0.050 |
Why?
|
| Hospitals, Veterans | 1 | 2003 | 44 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 486 | 0.050 |
Why?
|
| Cell Survival | 1 | 2003 | 304 | 0.050 |
Why?
|
| Stomach Diseases | 1 | 2002 | 7 | 0.050 |
Why?
|
| Choristoma | 1 | 2002 | 18 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 214 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 138 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 100 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2002 | 70 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2003 | 186 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2003 | 140 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 446 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 781 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2016 | 597 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 823 | 0.040 |
Why?
|
| Disinfection | 1 | 2018 | 6 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 2018 | 3 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2018 | 14 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 80 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 2011 | 22 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 30 | 0.030 |
Why?
|
| Adenoma | 1 | 2018 | 37 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2009 | 1910 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 66 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 988 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 207 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 335 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 134 | 0.030 |
Why?
|
| Stents | 1 | 2018 | 167 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 79 | 0.030 |
Why?
|
| Videotape Recording | 1 | 2016 | 13 | 0.030 |
Why?
|
| United States | 2 | 2018 | 4278 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 232 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 73 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 143 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 4137 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 169 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2005 | 510 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2005 | 439 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 58 | 0.020 |
Why?
|
| Animals | 1 | 2003 | 8579 | 0.020 |
Why?
|
| Cholagogues and Choleretics | 1 | 2011 | 3 | 0.020 |
Why?
|
| Technetium Tc 99m Lidofenin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 8 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2011 | 15 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 40 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 34 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 95 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 97 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 1246 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 73 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 81 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 101 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 86 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 110 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 149 | 0.020 |
Why?
|
| Video Recording | 1 | 2010 | 64 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 30 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 155 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 168 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 117 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2007 | 26 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2007 | 45 | 0.020 |
Why?
|
| Anesthesia | 1 | 2007 | 72 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 102 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 14 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 29 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 850 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 296 | 0.010 |
Why?
|
| Morbidity | 1 | 2005 | 103 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 170 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 755 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 305 | 0.010 |
Why?
|
| Mediastinum | 1 | 2004 | 14 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 53 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 417 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 402 | 0.010 |
Why?
|
| Ethnic Groups | 1 | 2006 | 483 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 431 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2002 | 194 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 561 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 1024 | 0.010 |
Why?
|